Juan Manuel Alonso‐Domínguez

Author

Hospital Universitario Fundación Jiménez Díaz ORCID

Also Known As

J Domínguez, J. Alonso-Dominguez, J. Dominguez, J. M. Alonso Dominguez, J. M. Alonso-Dominguez, J.M. Alonso, J.M. Alonso Dominguez, J.M. Dominguez, Juan Alonso‐Dominguez, Juan M Alonso-Dominguez

128

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Fundación Jiménez Díaz Hospital General Universitario de Alicante Doctor Balmis Hospital Universitario de Gran Canaria Doctor Negrín Hospital General Universitari de Castelló Hospital Universitario Ramón y Cajal

About

Juan Manuel Alonso‐Domínguez is an author at Hospital Universitario Fundación Jiménez Díaz specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	263
2	Health Sciences	5	5	111
3	Cell Biology	4	4	87
4	Engineering	1	1	13
5	Civil Engineering	1	1	13

Juan Manuel Alonso‐Domínguez

Publications

881

Citations

H-Index

Page 1

	Year	Citations
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms David P. Steensma, Martin Wermke, Virginia M. Klimek, Leukemia	2021	169
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) David P. Steensma, Martin Wermke, Virginia M. Klimek, Blood	2019	88
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice Valentín García‐Gutiérrez, Alejandro Luna, Juan Manuel Alonso‐Domínguez, Blood Cancer Journal Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematologyAsciminib Treatment	2021	43
A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations Elias Jabbour, Emma Searle, Maher Abdul‐Hay, Blood	2023	42
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia Bruno Paiva, María‐Belén Vídriales, Amparo Sempere, Leukemia Hematological MalignancyMedicineAcute Myeloid LeukemiaPethema Real-world StudyHematology	2021	40
A common novel splice variant of <i><scp>SLC</scp>22<scp>A</scp>1</i> (<i><scp>OCT</scp>1)</i> is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia Jacob Grinfeld, Gareth Gerrard, Mary Alikian, British Journal of Haematology Hematological MalignancyTumor BiologyChromatin StructureSlc22a1 ExpressionChronic Myeloid Leukaemia	2013	38
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia Alejandro Luna, Lucía Pérez‐Lamas, Concepción Boqué, Annals of Hematology	2022	36
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project Claudia Sargas, Rosa Ayala, Carmen Chillón, Haematologica	2020	32
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? David Martínez‐Cuadrón, Josefina Serrano, Cristina Gil, Leukemia AgingGeriatricsAge-related DiseasesOutcomes ResearchAging-associated Disease	2020	31
<scp>First‐in‐human</scp> study of <scp>JNJ</scp>‐63709178, a <scp>CD123</scp>/<scp>CD3</scp> targeting antibody, in relapsed/refractory acute myeloid leukemia Michael Boyiadzis, Pinkal Desai, Nikki Daskalakis, Clinical and Translational Science Mixed-phenotype Acute LeukemiaImmunologyPharmacotherapyImmunotherapyMyeloid Neoplasia	2022	27

Page 1